Q-omics provides the consensus-scored TENT5B profile across patient tissues and cancer cell-line models. TENT5B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, TENT5B is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, TENT5B RNA expression shows 13,811 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LGG, BLCA, and HNSC as cancer lineages where TENT5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TENT5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TENT5B survival associations across molecular data types. TENT5B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TENT5B RNA expression–survival associations across cancer types. High TENT5B expression shows unfavorable associations in LGG, LUSC, MESO and KICH, but favorable associations in UVM and ACC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for TENT5B RNA expression.
This table summarizes TENT5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TENT5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TENT5B shows lower tumor expression in BLCA, KIRC, THCA, HNSC, LUAD and KIRP. The BLCA box plot shows higher TENT5B RNA expression in normal versus tumor tissue (log2 FC = −4.181, t-test p < 0.001).
This table shows molecular features associated with TENT5B in patient tissues and cancer cell lines. In patient samples, TENT5B shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TENT5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
